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Introduction: Early rectal cancer (ERC) assessment
should include prediction of the potential excision
plane to safely remove lesions with clear deep margins
and feasibility of organ preservation.
Method: MRI accuracy for differentiating ≤T1sm2
(partially preserved submucosa) or ≤T2 (partially
preserved muscularis) versus >T2 tumours was
compared with the gold standard of pT stage T1sm1/2
versus ≤pT2 versus >pT2. N stage was also compared.
The MRI protocol employed a standard surface phased
array coil with a high resolution (0.6×0.6×3 mm
resolution). The staging data were analysed from a
prospectively recorded database of all ERC (≤mrT3b)
treated by primary surgery.
Results: Of 65 <mrT3b tumours, 45 were ≤pT2 and
14 were ≤pT1sm2. MRI accuracy for ≤T1sm2 was
89% (95% CI 63% to 87%), positive predictive value
(PPV) 77% and negative predictive value (NPV) 92%,
and for ≤T2 89% (95% CI 79% to 95%), PPV 93%
and NPV 81%. Interobserver agreement between two
experienced radiologists was >0.7 suggesting good
agreement. 44 out of 65 patients underwent radical
surgery and 22 out of 44 were ≤mrT2. MRI accuracy
to predict lymph node status was 84% (95% CI 70%
to 92%), PPV 71% and NPV 90%. Among the 21 out
of 65 (32%) patients undergoing local excision or
TEM, 20 out of 21 were staged as MR≤T2 and
confirmed as such by pathology. On follow-up, none
had relapse. If the decision had been made to offer
local excision on MRI TN staging rather than clinical
assessment, a significant increase in organ
preservation surgery from 32% to 60% would have
been observed (difference 23%, 95% CI 9% to 35%).
Conclusions: MRI is a useful tool for
multidisciplinary teams (MDTs) wishing to optimise
treatment options for ERC; these study findings will be
validated in a prospective multicentre trial.
INTRODUCTION
The slow evolution of cancer in polyps was
ﬁrst reported in 1975 by Muto et al1 at St
Marks Hospital in 1975 and led directly to
the implementation of colorectal screening.
Through screening, an increase in detection
of early rectal cancers (ERC) and signiﬁcant
polyps may improve survival outcomes by
intercepting the polyp to cancer sequence.
An unfortunate consequence of screening
has been the high rate of patients with ERC
Summary box
What is already known about this subject?
▸ The proportion of detected T1 colorectal cancers
is highly increasing due to a number of screen-
ing programmes with up to 30% of screen-
detected cancers being identified as Dukes’ A.
▸ Endoluminal ultrasound has not proven to be
effective, as preoperative staging does not offer
sufficient accuracy or influence the rate of R1
resection and outcomes.
▸ High-resolution MRI is widely accepted as a
gold standard of advanced rectal tumours
spread assessment; however, MRI is not always
relied on as a primary tool for staging early
rectal cancer (ERC) as a tendency to inaccurately
stage lesions as T1/2 without precisely specify-
ing the depth of invasion has previously been
observed.
What are the new findings?
▸ High-resolution MRI enables differentiation of
partial versus full submucosal invasion with
89% accuracy when tested prospectively in
patients with ERC.
▸ Eighty-nine per cent accuracy was observed of
detection of partial or full preservation of the
muscularis propria.
▸ MRI specificity to predict node-negative disease
in ≤pT2 tumours was 84%.
How might it impact on clinical practice in
the foreseeable future?
▸ This paper suggests that MRI could be used as
a guiding tool to plan endoscopic and surgical
planes in ERC and can be a useful tool for multi-
disciplinary teams (MDTs) wishing to optimise
treatment options for ERC.
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being subjected to major total mesorectal excision
(TME) surgery, permanent stomas and even preopera-
tive radiotherapy despite early disease; the National
Bowel Cancer Audit (NBOCAP report, 2015)2 showed
that a signiﬁcant proportion of patients with ERC had
T1N0 disease, yet underwent major resection surgery
without any option for less radical treatments.
Conversely, the UK transanal endoscopic microsurgery
(TEM) database suggests that ∼30% of tumour consid-
ered as ERC based on clinical endoscopic assessment
had more advanced disease, with evidence of spread
beyond the muscularis propria (MP) on histopathology
following TEM excision. No signiﬁcant difference has
been found in the depth of TEM excision or R1 rate
between the patients who underwent endoluminal ultra-
sound (EUS) before TEM and those who did not
(p=0.73) with EUS understaging taking place in 32.7%
of patients.3 Therefore, the current standards of endo-
scopic and EUS assessment appear insufﬁcient to iden-
tify patients suitable for potentially less radical treatment
and the lack of any current robust preoperative staging
method means that decision and discussion of such
treatment options cannot currently be offered
consistently.
The national SPECC (Signiﬁcant Polyp and Early
Colorectal Cancer) initiative was a consequence of a
major problem we are currently facing—an overtreat-
ment and undertreatment of ERC/signiﬁcant polyps.
MRI has largely been disregarded as a method of staging
ERC; however, the majority of publications have reported
that MRI is not as useful compared with EUS for staging
these lesions, although this has not been supported by
signiﬁcant evidence in either direction.4–7 In the late
1990s, a high-resolution technique for staging advanced
rectal cancers and the principles for staging advanced
rectal cancers were developed that enabled identifying
the layers of the rectal wall with sufﬁcient resolution to
assess the submucosa and the MP.8 In subsequent studies,
when formally compared with pathology, the depth of
spread on MRI has been found to agree with the corre-
sponding histopathology measurements to within
1 mm.9 10 The degree of agreement was the best for the
earlier stage tumours; therefore, if the attempt is made to
make these measurements within the rectal wall, it is
logical to assume that the performance should be similar.
We therefore hypothesise that by using high-resolution
MRI, it should be possible to identify tumour depth of
invasion within the rectal wall to enable identiﬁcation of
patients suitable for local excision approaches. The aim
of this study was therefore to test the MRI diagnostic
accuracy of ERC staging in terms of assessing the sub-
mucosa, MP and the depth of tumour invasion within the
rectal wall against the gold standard of histopathology in
a cohort of patients prospectively staged in our institu-
tion. The clinical impact of this assessment would deter-
mine if the plane of excision needed to achieve a clear
deep margin proposed using the MRI is accurate enough
for surgeons and endoscopists to plan their intervention




Our study protocol was prospectively registered with our
local research and development ofﬁce and approved as
a service evaluation project. We reviewed our prospect-
ively collected and scored database of imaging and path-
ology records between 2010 and 2014. Since the data
had been recorded prospectively prior to MDT and sur-
gical resection, the scans were centrally reviewed by a
consultant radiologist (observer 1) with more than
15 years of gastrointestinal (GI) radiology experience
who was blinded to ﬁnal histopathology data. Results of
the prospectively collected MRI reports were compared
with ﬁnal histopathology of the resected specimens. All
MRIs were scored separately by a second radiologist
(observer 2) with 8 years of GI radiology experience.
Participants
The Royal Marsden Hospital Rectal Cancer database was
used to identify patients with rectal cancer staged by
MRI as ≤T3b. Inclusion criteria were as follows: patients
under 18, had rectal cancer MRI staging and underwent
surgical resection. Patients were excluded if they: had
other primary cancers found at or before diagnosis, if
no preoperative MRI was available or preoperative MRI
T stage was >T3b, mrCRM and mrEMVI positivity, or if
they received any preoperative therapy.
Test methods
Since 2010, our policy was to report ERC using a speciﬁc
reporting pro forma. Tumours staged as T2 or less were
prospectively documented using the following ‘sm’
classiﬁcation:
▸ no MR-macroscopic evidence of submucosal invasion
—benign polyp;
▸ macroscopically visible spared submucosa (at least
1 mm or more) and fully intact MP—T1sm1/
T1sm2;
▸ no submucosa preserved (<1 mm) with macroscopic-
ally intact ﬁbres of outer layer of the MP—sm3/early
T2.
MRI technique
MR examinations were performed on a 1.5 T MR system
(Siemens) with a body-matrix coil centred over the
pelvis. High-resolution T2w turbo spin echo (TSE) scans
were acquired in coronal and sagittal planes, followed by
oblique-axial scans (perpendicular to the long axis of
the rectum with 160 mm ﬁeld of view (FOV), 3 mm slice
thickness, no interslice gap, a matrix of 256×256 and a
minimum of 4 number of signal averages (NSA)). No
contrast was used during MRI examination. No
diffusion-weighted images (DWI) were undertaken.
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Image interpretation
MRI assessment of tumour depth was performed at the
level of the invasive border in semianular tumours or at
the level of ﬁbromuscular stalk if a polypoidal lesion was
suspected. For semianular tumours, the presence or
absence of a preserved submucosal layer at the central
invasive portion was the main staging factor (in accord-
ance with previously published guidelines11).
The degree of preservation of the submucosal layer
seen on MRI as a hyperintense plane between tumour
and MP (ﬁgure 1A,B) was recorded. A measurement of
(≥1 mm) preserved submucosa was used as a deﬁnition
for partial rather than full submucosal invasion and any
such tumour would then be classiﬁed on MRI as T1 sm1
or sm2, depending on the maximal degree of preserva-
tion of the submucosal layer in any one plane. If no
hyperintense submucosal layer was identiﬁed between
the tumour and the muscularis but the muscularis layer
was completely preserved (ﬁgure1C,D), the tumour was
staged as T1sm3/early T2.
Tumours with >1 mm preservation of MP were classi-
ﬁed as T2, and those with <1 mm MP preservation or
spread beyond the muscularis as T3a-b (depending on
the depth of mesorectal invasion in millimetres).
Original pro-forma reports as discussed and presented
at colorectal weekly MDT were analysed for the purposes
of this study. The policy of the MDT was to offer primary
surgery for ERC without any preoperative radiotherapy
regardless of nodal status provided that no extramural
venous invasion (EMVI) or circumferential resection
margin (CRM) involvement was evident on MRI. However,
there was no implemented policy to offer local excision
based on MRI assessment during this audit period.
We subsequently evaluated the accuracy of MRI in
deﬁning endoscopic/surgical planes for ERC on the
basis of the tumour depth invasion into the rectal wall
comparing MRI results to ﬁnal histopathology ﬁndings.
We tested two models of possible endoscopic/surgical
intervention based on preoperative MRI (ﬁgure 2 and
table 1 for two scenarios).
Figure 1 (A) Submucosa has a hyperintense signal on MRI (red arrow) which should be considered partially or fully preserved
if at least 1 mm visible on high-resolution T2-WI. Findings confirmed on histopathology (B). (C) If no hyperintense signal present
between the tumour invasion portion and muscularis propria, full invasion of the submucosal layer should be considered.
Findings confirmed on histopathology (D).
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In the ﬁnal analysis, we calculated MRI accuracy for two
scenarios regardless of preoperative biopsy ﬁndings (scen-
ario 1: feasibility of MRI to identify tumours with minimal
submucosal invasion (≤T1sm2); scenario 2: feasibility of
MRI to identify tumours with no submucosal preservation
but partial or full invasion of the MP (≤T2)).
In patients who had undergone total mesorectal resec-
tion during the evaluation period, we also compared the
accuracy of MRI in identifying patients with malignant
lymph nodes.
The MRI scans were read by a second independent
observer to measure interobserver agreement of MRI
staging accuracy of ERC. Anonymised scans were scored
by the observer 2 who was blinded to the histopathology
results and results of the MRI reports from the observer
1. All of the scans were analysed during three sessions
with 20±3 cases per session using the same reporting pro
forma as by the observer 1. Scans were staged according
to the TNM classiﬁcation and then categorised into
three groups (≤T1sm2, ≤T2, >T2).
Statistical analysis
Data were tabulated and entered into a spreadsheet. All
statistical analyses were performed using Microsoft Excel
V.14.4.5 (Redmond, Washington, USA 2011) and IBM
SPSS V.23.0 (IBM Corp, New York, USA, 2013).
The primary end point was the sensitivity, speciﬁcity
and accuracy of MRI calculated for both scenarios.
MRI accuracy for staging and deﬁning endoscopic and
surgical planes for local excision was calculated from
histology data using cross tables. CIs for the sensitivity
Figure 2 Flow chart demonstrating potential treatment algorithms based on MRI-defined endoscopic and surgical planes. Blue
colour indicates scenario 1 and pink colour indicates scenario 2.
Table 1 MRI vs histopathology in identifying rectal
cancer with partial submucosal invasion (T1sm2 or less)
Histo ≤T1sm2 Histo >T1sm2
(A) Scenario 1
MR ≤T1sm2 True +ve False +ve
MR >T1sm2 False −ve True −ve
≤Histo T2 Histo >T2
(B) Scenario 2
≤MR T2 (≥1 mm
clear to MP)
True +ve False +ve
MR T2
(<1 mm clear to MP+)
False −ve True −ve
MP, muscularis propria.
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and speciﬁcity for a binomial probability were calculated
using the exact method.
For those patients treated by TME, sensitivity analysis
was performed to evaluate MRI accuracy in assessing
lymph node status.
The hypothetical effect of an MRI-directed assessment
of likely suitability for a local excision pathway rather
than the actual MDT decision based predominantly on
clinical data was also calculated as a secondary end
point. Differences in proportions of patients undergoing
radical surgery according to clinical assessment and pro-
posed having radical resection according to MRI staging
were calculated using Newcombe method 10.12
For the interobserver agreement between the two radiol-
ogists, Cohens κ level was used to calculate results. A value
of p<0.05 was chosen as the signiﬁcance level for κ statis-
tics. The value of κ statistics was interpreted according to
Altman.13 Agreement lies between 0 and 1, where 0 is indi-
cative of no agreement and 1 indicates complete agree-
ment. ‘Very good/near perfect’ agreement is considered
as a κ of 0.81–1.00; ‘good’ agreement as a κ of 0.61–0.80;
‘moderate’ agreement as a κ of 0.41–0.60; ‘fair’ agreement
as a κ of 0.21–0.40; and ‘poor’ agreement as a κ of <0.2.
RESULTS
Participants
Overall, 65 patients with a median age of 69 (34–91) ful-
ﬁlled the MRI staging inclusion criteria of mrT3b or less
(ﬁgure 3 presents a ﬂow chart of participants according
to STARD); demographics are presented in the table 2.
In 20% (13/65) of the patients, tumours were pre-
operatively MR-categorised as lesions with no or minimal
invasion of the submucosal layer (no invasion, T1sm1,
T1sm2). Of these 13 patients, 10 were conﬁrmed as
such on pathology. Thirty-one patients (47%) had mr
T1sm3-T2 stage with no MR-evidence of tumour breach-
ing through the MP. Of these 31 patients, 24 were
proven to be pT1sm3-T2 on histopathology, and 21
patients had mrT stage >T2 with 17 out of 21 conﬁrmed
to be pT3 disease.
Overall 44 out of 65 patients underwent radical
surgery (table 3) and 22 were staged as T2 or less by
MRI. Pathological nodal status was positive in 7 out of 22
patients, 4 of whom had been staged as node-positive on
MRI. Thus 15 out of 18 patients were correctly predicted
as pT2 or less and pathology node-negative. Among the
21 out of 65 (32%) patients undergoing local excision
or TEM, 20 out of 21 were staged by MRI as T2 or less
and conﬁrmed as such by pathology. On follow-up, none
had lymph node relapse. If the decision had been made
to offer local excision on MRI TN staging rather than
clinical assessment, a signiﬁcant increase in organ pres-
ervation surgery from 32% to 58% would have been
observed (difference 26%, 95% CI 9% to 41%).
In one case, AP resection was performed for a benign
large lower rectal adenoma, which was not proven to be
malignant on the preoperative biopsy but was clinically
too large and difﬁcult for removal by local excision (the
patient was counselled with regard to radical surgery for
a benign lesion).
Test results
Results of MRI accuracy to predict safe resection plane
According to the table 4 results, MRI accuracy in identi-
fying a safe submucosal plane for non-invasive aden-
omas, T1sm1-sm2 tumours (scenario 1—tumours
≤T1sm2) was 89% (95% CI 63% to 87%), sensitivity
71%, speciﬁcity 94%, PPV 77% and NVP 92%.
When compared with histopathology data, MRI showed
89% (95% CI 79% to 95%) accuracy, 91% sensitivity, 85%
speciﬁcity, 93% PPV and 81% NPV in identifying a safe
MP plane, therefore differentiating tumour with full
submucosal invasion but conﬁned to MP versus tumour
with spread beyond the MP (tumour ≤T2—scenario 2).
Results of interobserver agreement
Results of the κ statistic for the second observer when
compared with the central reviewer (observe 1) can be
seen in table 5. κ Agreement was calculated of value
0.734, with p<0.005 indicating a good agreement
(weighted κ was 0.741).
Figure 3 Diagram reporting flow of participants though the study (according to STARD recommendations).
Balyasnikova S, Read J, Wotherspoon A, et al. BMJ Open Gastro 2017;4:e000151. doi:10.1136/bmjgast-2017-000151 5
Open Access
Result of MRI accuracy to predict lymph node status
When compared with ﬁnal histopathology in patients
who underwent radical resection, MRI accuracy in pre-
dicting lymph node status was 84% (95% CI 70% to
92%), PPV 71% and NPV 90%.
Overall MRI results to predict eligible patients for organ
preservation treatment
Overall radical surgery was undertaken in 68% (44/65)
of patients and 32% (21/65) patients were treated with
local excision. According to MRI ﬁndings (T and N
MR-staging), another 18 patients could potentially have
been offered local excision as their tumours were staged
as T2N0 or less (table 3). Therefore, if the decisions had
been made to offer local excision based on MRI ﬁndings
rather than clinical assessment, a further 26% of patients
would have received less radical surgery, making a total
of 38 out of 65 eligible on MRI compared with 21 out of
65 from clinical assessment alone. This would have cor-
responded to a signiﬁcant increase in organ preserva-
tion surgery from 32% of clinically staged ERC to 58%
of MRI-staged ERC (95% CI 9% to 41%).
DISCUSSION
Implementation of bowel cancer screening has
increased the proportion of colorectal cancer identiﬁed
as early stage. About 30% of screen-detected cancers are
Dukes’ A14 compared with 10% of the non-screened
population. Patients with ERC can only be offered the
correct treatment modality if they are identiﬁed and
accurately staged before resection. Organ preservation
avoids the extra mortality of TME and abdominoperi-
neal excision of rectum (APER) and morbidity such as
permanent stoma, sexual dysfunction and a prolonged
hospital stay and if appropriate patients can be safely
identiﬁed, the option of organ preservation is a prefer-
able option for the majority.15 Preoperative assessment
of tumour depth invasion is crucially important in deter-
mining endoscopic and surgical planes. Paris morph-
ology, pit pattern and the lift signs are used by expert
endoscopists to stratify the risk of submucosal invasion.
However, the interobserver variability and accuracy of
these tools in routine UK practice have not been
audited or investigated. It is likely that other methods
may well improve outcomes given that 33% of locally
excised lesions in the TEM registry were unexpectedly
malignant having been assessed by experienced endos-
copists and that removal of such lesions was associated
with a statistically signiﬁcantly higher chance of an
involved margin.16 17 Preoperative imaging, based on
endorectal ultrasound (ERUS), has not been proven to
be reliable in selecting the correct patients, for example,
in a multicentre German study of over 3500 patients’
EUS, Ptok et al found an accuracy of 65% for T
staging.18 At present, ERUS has not established itself in
assessing ERC in UK practice, for example, of 487
patients undergoing TEM, only 148 were staged by
ERUS with no difference in the rates of resection
margin positivity or outcomes in patients having ERUS.3
MRI is the gold standard for advanced disease;
however, it is not yet used as a staging tool for an early
disease.
Internationally accepted standards suggest that only
T1 rectal tumours with minimal invasion of the sub-
mucosal layer—sm1 according to Kikuchi classiﬁcation
—should be considered eligible for local excision.
However, the reality shows a different practice. Haboubi
and Salmo19 previously reported that thickness of the
submucosal layer varies greatly among the individuals









<65 6 9 7 22
≥65 7 22 14 43
Sex
Male 8 17 15 40
Female 5 14 6 25
Tumour distance from the anal verge
≤6 cm 6 14 4 24
>6 cm 7 17 17 41
mr N Stage
mrN0 13 26 11 50
mrN1-N2 0 5 10 15
p N stage
pN0 3 14 14 31
pN1-N2 0 7 6 13
n/a 10 10 1 21
Type of surgery performed
LE 6 5 0 11
TEMS 4 5 1 10
AR 3 21 18 42
Exenteration 0 0 2 2
Quadrant of rectal wall infiltrated by tumour
Anterior 4 7 6 17
Lateral 6 15 12 33




4 0 0 4
T1sm1 1 0 0 1
T1sm2 5 4 0 9
T1sm3 2 7 0 9
T2 1 17 4 22
T3* 0 0 4 4
T3a 0 2 4 7
T3b 0 0 5 4
T3c 0 1 3 4
T4 0 0 1 1
Total 13 31 21 65
*Missing histopathology data about the depth of tumour invasion
into the mesorectum.
AR, anterior resection; LE, local excision; n/a, not applicable
(patients were treated with local excision), TEMS, transanal
endoscopic microsurgery.
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and cannot be appropriately assessed in the absence of
MP within the surgical specimen. Whenever the MP is
lacking in the specimen, histopathological assessment of
the submucosal depth invasion and differentiation of
T1sm1/sm2 and even sm2/sm3 become challenging. It
has also been stated that budding, lymphovascular inva-
sion and tumour differentiation are prognostic factors
that determine the need for either adjuvant therapy or
subsequent completion/salvage surgery but the validity
of these prognostic measures has been questioned
because of the lack of reproducibility of these factors.
This has resulted in the review of the current standards
of assessing such lesions. The emerging consensus is
that rather than using a method with poor inter-observer
agreement, absolute measures of depth and width are
more reliable and therefore prognostically more
secure.20 It has also been shown that depth and width of
mucosal invasion predict the lymph node metastasis in
ERC.21
There is a paucity of good-quality data evaluating the
performance of high-resolution MRI in staging ERC.
Traditionally, it has not been relied on as a primary tool
Table 3 Type of surgery performed
pT stage Type of surgery
TotalAR LE TEMS Exenteration
Benign
adenoma Nx
0 2 (2—mr no invasive
cancer)





1 (1—mr no invasive cancer) 0 0 0 1
T1sm1 0 0 1 (1—mrTsm2N0) 0 1
T1sm2Nx 0 3 (3—mrT1sm2-3N0) 3 (3—mrT1sm2-T2N0) 0 6
T1sm2N0 3 (3—mrT1sm2-3N0) 0 0 0 3
T1sm3Nx 0 5 (5—mrT1sm3N0) 1 (1—mrT1sm3N0) 0 6
T1sm3N+ 1 (1—mrT2N+) 0 0 0 1
T1sm3N0 2 (2—mrT1sm3N0) 0 0 0 2
T2Nx 0 1 (mrT1sm3N0) 3 (3—mrT1sm3-T2N0) 0 4
T2N+ 5 (2—mrT2N+, 1—mrT3bN+, 2
-mrT2N0)
0 0 0 5
T2N0 13 (9—mrT1sm3-T2N0; 4—
mr>T2N0)
0 0 0 13
T3aN+ 1 (1—mrT2N0) 0 0 0 1
T3aN0 5 (5—mrT3a-bN0) 0 0 1 (1—
mrT3aN0)
6
T3bNx 0 0 1 (1—mrT3bN+) 0 1
T3bN+ 3 (3—mrT3bN+) 0 0 0 3
T3cN+ 1 (1—mrT2N+) 0 0 0 1
T3cN0 2 (2—mrT3bN+) 0 0 1 (1—
mrT3bN+)
3
T3N+ 1 (1—mrT3bN+) 0 0 0 1
T3N0 3 (2—mrT3N0; 1—mrT3bN+) 0 0 0 3
T4N+ 1 (mrT3bN+) 0 0 0 1
Total 42 11 10 2 65
*Depth of invasion into mesorectum not recorded by pathologist.
AR, anterior resection; LE, local excision; TEMS, transanal endoscopic microsurgery; TxNx, patients who potentially could have less radical
surgery according to mrTN stage.




TotalT0 T1sm1 T1sm2 T1sm3 T2 ≥T3a
Partial invasion of the submucosa
(scenario 1)
mrT0,T1sm1,T1sm2 4 1 5 2 1 0 13
Full invasion of the submucosa,
partially or fully spared MP (scenario 2)
mrT1sm3-T2 0 0 4 7 17 3 31
≥T3a-T3b 0 0 0 0 4 17 21
Total 4 1 9 9 22 20 65
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for staging ERC as it is perceived that MRI should not
be used for staging ERC, with a tendency to overstage or
inaccurately stage lesions as T1/2 without precisely speci-
fying the depth of invasion. On imaging, differentiation
between ‘sm’ subcategories remains challenging; never-
theless we wanted to test the ability of MRI to identify
potentially safe submucosal and MP planes. In this ana-
lysis, we reviewed the hypothetical impact on patient
treatment if an MRI-directed approach to local excision
had been followed. Therefore, a retrospective
hypothesis-generated study to determine if the criteria
for identifying suitable patients are accurate was under-
taken. Results have shown that 89% patients were cor-
rectly identiﬁed for partial submucosal invasion and
89% were accurately staged as potentially suitable for
full thickness excision (patients with full submucosal
invasion but spared MP); therefore, MRI shows better
results than current standards that identify accurately
only about a third of patients. Furthermore, the identiﬁ-
cation of patients suitable for primary local excision
based on MRI node-negative prediction is such that only
3 out of 18 patients with node-positive status were
missed but a further 15 patients were correctly identiﬁed
as node-negative. This has implications for patient dis-
cussions on the use of adjuvant radiotherapy in ERC
rather than completion radical surgery. In our institu-
tion, adjuvant radiotherapy is reserved only for those
staged on ﬁnal pathology as pTsm3 or more or where
there is margin involvement and surveillance offered to
the remainder. Following this policy, we have not
observed disease recurrence after a minimum of
3.5 years follow-up.22 This paper suggests a new
approach to MRI imaging of early disease and the ﬁnd-
ings support that MRI may be able to accurately identify
the safe resection plane for ERC.
One of the limitations of this study is that κ for the
radiologists has been assessed among radiologists experi-
enced in reporting rectal cancer as this is a single-
centred study and this needs to be prospectively tested
in order to determine whether this can change practice
nationally and globally. However, there are studies under
way and are in the prospective MINSTREL (MrI iN
Staging RECTAL poLyps) study which is completing its
recruitment using precisely these deﬁnitions. If it is
proven that MRI performance is reproducible in differ-
ent centres, then it will lead to an important improve-
ment in staging.
It is considered that the depth of the submucosal inva-
sion predicts the rate of lymph node metastases. The
concern of occult lymph node metastases in tumours
>T1sm1 has limited organ-sparing treatment. Results of
this study show that MRI prediction of node-negative
status is >80% when morphological characteristics are
evaluated on high-resolution MRI scans and the ques-
tion is whether patients should be deprived of the
opportunity to undergo organ preservation based only
on the degree of tumour invasion into the submucosa,
bearing in mind that 80% of patients with pT1sm2-sm3
tumours will have no metastases within the mesorectal
lymph nodes or even less if there are no other adverse
features. Furthermore, the potential to relapse within
the mesorectum could then be monitored by MRI sur-
veillance (which was not available in older TEM and
local excision studies).
All these potential risks and beneﬁts of organ pre-
serving treatment should be discussed with patients
and decision to treat should be based on patients’
choice as well.
It has been suggested that radiotherapy can be offered
to all ERC deﬁned as T2 or less prior to TME surgery
because ﬁrst, there is no reliable staging method to dis-
tinguish between T1 and T2 tumours and second, com-
plete responders following TME could avoid further
surgery. If this policy had been followed, over 36 out of
44 patients with mrT2N0 or less would have been irra-
diated for node-negative disease and potentially would
have suffered a higher comorbidity rates associated with
TEM defect healing in an irradiated rectum.23 As the
SPECC programme has highlighted, the overtreatment
of ERC may not be in the patients’ interest. This study,
therefore, shows the use of preoperative imaging in pre-
venting overtreatment and providing patients with
robust prognostic information to make an informed
choice about the decision and to understand the risk
versus beneﬁts of treatment options/surgical decisions.
The next phase is to determine whether this is repro-
ducible in the multicentre setting and ﬁnally if it proves
to be reproducible in the multicentre study (the
MINSTREL study), then this will be used as a basis for
offering more patients with ERC the possibility of organ
preservation.
CONCLUSION
This analysis shows that high-resolution MRI assessment,
with particular attention paid to the degree of preserva-
tion of the submucosa and MP layers at the invasive
margin of the tumour, is a reliable method of staging
depth of invasion in ERC. If reproducible and con-
ﬁrmed in the prospective MINSTREL trial, there are
very few resource barriers to prevent wider UK adoption
of MRI as a standard of care for ERC.
Table 5 Interobserver agreement
Observer 2
Observer 1 Category ≤T1sm2 ≤T >T Total
≤T1sm2 10 3 – 13
≤T 3 24 4 31
>T 1 20 21
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